Glenmark Pharma shares: The company's unit Glenmark Specialty S.A. signed an exclusive licensing deal with China’s Hengrui Pharma for Trastuzumab Rezetecan, a next-gen HER2-targeting ADC. The pact includes an upfront payment of $18 million, milestone payouts of up to $1.093 billion, and royalties on sales.
